Equities analysts expect Proteostasis Therapeutics Inc (NASDAQ:PTI) to report earnings per share of ($0.65) for the current quarter, Zacks reports. Two analysts have provided estimates for Proteostasis Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.72). Proteostasis Therapeutics posted earnings per share of ($0.38) during the same quarter last year, which would suggest a negative year over year growth rate of 71.1%. The company is scheduled to issue its next quarterly earnings report on Thursday, March 29th.
On average, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($2.47) per share for the current financial year, with EPS estimates ranging from ($2.56) to ($2.40). For the next year, analysts forecast that the firm will post earnings of ($2.34) per share, with EPS estimates ranging from ($2.82) to ($1.89). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Proteostasis Therapeutics.
Proteostasis Therapeutics (NASDAQ:PTI) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.16. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%. The business had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.38 million.
PTI has been the topic of a number of research analyst reports. ValuEngine cut shares of Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Proteostasis Therapeutics in a research note on Tuesday, December 19th. Zacks Investment Research cut shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Leerink Swann boosted their target price on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a research note on Tuesday, December 12th. Finally, Robert W. Baird boosted their target price on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $16.00.
Proteostasis Therapeutics (NASDAQ:PTI) traded up $0.20 during trading on Friday, reaching $4.49. 154,308 shares of the company traded hands, compared to its average volume of 642,117. Proteostasis Therapeutics has a 1-year low of $1.41 and a 1-year high of $16.67. The stock has a market capitalization of $142.05, a PE ratio of -2.02 and a beta of 9.36.
In related news, major shareholder Cormorant Asset Management, Ll sold 504,027 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $4.88, for a total transaction of $2,459,651.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Enterprise Associates 12 New purchased 2,000,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The shares were acquired at an average price of $5.00 per share, for a total transaction of $10,000,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 2,100,000 shares of company stock worth $10,500,000 over the last 90 days. 17.40% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of PTI. Goldman Sachs Group Inc. increased its holdings in Proteostasis Therapeutics by 364.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock worth $243,000 after acquiring an additional 40,731 shares during the period. Susquehanna International Group LLP bought a new position in shares of Proteostasis Therapeutics in the 2nd quarter worth $254,000. Dimensional Fund Advisors LP bought a new position in shares of Proteostasis Therapeutics in the 2nd quarter worth $296,000. Sabby Management LLC increased its holdings in shares of Proteostasis Therapeutics by 109.6% in the 2nd quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after buying an additional 65,451 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Proteostasis Therapeutics by 425.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,124,602 shares of the company’s stock worth $2,361,000 after buying an additional 910,550 shares during the last quarter. 51.80% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/29/zacks-brokerages-expect-proteostasis-therapeutics-inc-pti-to-post-0-65-eps.html.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.